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Tumour angiogenesis and tumour cell proliferation as prognostic
indicators in gastric carcinoma
K Maeda, Y-S Chung, S Takatsuka, Y Ogawa, N Onoda, T Sawada, Y Kato, A Nitta, Y
Arimoto, Y Kondo and M Sowa
First Department ofSurgery, Osaka City University Medical School, Japan.
Summary Tumour growth depends on neovascularisation and tumour cell proliferation. Factor VIII-related
antigen (F-VIII RA) localises to vascular endothelium. Expression of proliferating cell nuclear antigen
(PCNA) is correlated with cell proliferation. We investigated the correlation between the expression of these
antigens and prognosis in gastric carcinoma. A total of 108 specimens resected from patients with gastric
carcinoma were investigated by staining with monoclonal antibodies against F-VIII RA and PCNA. Mic-
rovessel count (MVC; the mean number of microvessels in the five areas of highest vascular density at 200 x
magnification) and PCNA labelling index (PCNA LI; percentage of positive cells in more than 500 tumour
cells) were detennined. The results showed that prognosis was significantly worse in patients who had a
tumour with a high MVC (16 or greater) or a high PCNA LI (42% or greater) than in those patients who had
a tumour with a low MVC (less than 16) or a low PCNA LI (less than 42%). Furthermore, MVC was
significantly associated with the risk of hepatic recurrence. In conclusion, both MVC and PCNA LI may be
good prognostic indicators in patients with gastric carcinoma.
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Recently, it has been suggested that the degree of tumour
angiogenesis is related to malignant potential (Folkman,
1990; Bosari et al., 1992). Cellular proliferative activity has
also been suggested as a useful marker for the malignant
potential of various carcinomas (Sowa et al., 1988; Van
Dierendonck et al., 1989). In recent years, many studies have
reported on the relationship between tumour angiogenesis,
tumour cell proliferation and clinical outcome (Bouzubar et
al., 1989; Weidner et al., 1992; Gasparini et al., 1994).
Weidner et al. (1992) have shown that, in patients with breast
cancer, both relapse-free and overall survival rates decrease
with increasing microvessel count. In this study microvessels
were highlighted by staining for factor VIII-related antigen
(F-VIII RA) or von Willebrand factor, which can be
localised to vascular endothelium in tissue sections by
immunofluorescence and immunoperoxidase techniques. Pro-
liferating cell nuclear antigen (PCNA), an auxiliary protein
for DNA polymerase 6, plays an important role in DNA
synthesis and is thought to be localised to nuclei, particularly
during late GI and S-phases (Garcia et al., 1989; Landberg et
al., 1990). In this context, PCNA has drawn attention as a
marker for cell proliferation.
In this study, we investigated the correlation between prog-
nosis and angiogenesis and cell proliferation in gastric cancer
as demonstrated by immunohistochemical staining of F-VIII
RA and PCNA respectively.
Materials and methods
Clinical material
Resected specimens from 108 patients with gastric carcinoma
who underwent curative surgical resection at our institution
were studied. The patients ranged in age from 28 to 78 years
(mean age 59.3 years); 90 were men and 18 were women. No
patient had received chemotherapy or radiation therapy
before the surgery. The General Rules for Gastric Cancer
(Japanese Research Society for Gastric Cancer, 1981) were
used for the pathological diagnosis and classification of
variables. In this study, tumours were divided into two his-
tological subgroups: differentiated type, which consisted of
papillary and tubular adenocarcinomas; and undifferentiated
type, which consisted of poorly differentiated adenocar-
cinomas, signet ring cell carcinomas and mucinous adenocar-
cinomas. All patients were followed up for at least 5 years
after surgery and routinely studied by diagnostic imaging
(computerised tomography or ultrasonography) once or twice
a year. The type of recurrence was established by diagnostic
imaging, serum level of tumour marker, cytology, biopsy or
surgery, and was classified as hepatic recurrence, peritoneal
recurrence or another type of recurrence. Almost all patients
had only one site of recurrence. In patients who had multiple
sites of recurrence, the type of recurrence was determined at
the time of first relapse.
Specimens were fixed in 10% formaldehyde and embedded
in paraffin. Four-micrometre-thick sections were cut and
mounted on glass slides.
Antibodies and reagents
As primary antibodies, mouse monoclonal antibodies F8/86
(which recognises F-VIII RA) and PC1O (which recognises
PCNA) were used at a dilution of 1:200. These antibodies
were purchased from Dakopatts (Glostrup, Denmark). Nor-
mal rabbit serum, normal mouse immunoglobulin G (IgG),
biotinylated rabbit anti-mouse IgG, streptavidin-peroxidase
reagent and diaminobenzidine were purchased from Nichirei
Corporation (Tokyo, Japan).
Immunohistochemical techniques
Immunohistochemical studies were performed by the strep-
tavidin-biotin method. Sections were dewaxed in xylene,
taken through ethanol and then incubated with 0.3% hyd-
rogen peroxide in methanol for 30 min to block endogenous
peroxidase activity. Sections were then washed in phosphate-
buffered saline (PBS) and incubated in 10% normal rabbit
serum for 20 min to reduce non-specific antibody binding.
Specimens were then incubated with primary antibodies at
room temperature for 2 h, followed by three washes with
PBS. Sections were then incubated with biotinylated rabbit
anti-mouse IgG at a dilution of 1:100 for 30 min followed by
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three washes. Slides were then treated with streptoavidin-
peroxidase reagent for 30 min at a dilution of 1:100 and were
washed with PBS three times. Finally, slides were incubated
in PBS containing diaminobenzidine and 1% hydrogen
peroxide for 10min, counterstained with methyl green and
mounted. Normal mouse IgG was substituted for primary
antibody as the negative control. Slides were interpreted for
antigen expression by two investigators without knowledge
of the corresponding clinicopathological data. Individual
tumours demonstrated considerable heterogeneity in mic-
rovessel density and the expression of PCNA. Therefore, in
each case, several blocks of the same tumour were retrieved
and sections were cut and stained by antibodies. Microvessel
counting and PCNA scoring were determined among the five
areas with the highest density of these antigens from all tissue
blocks.
Microvessel counting
Any brown-staining endothelial cell or cluster of endothelial
cells that was clearly separate from adjacent microvessels,
tumour cells and other connective tissue elements was con-
sidered as a single vessel (Figure 1). Branching structures
were counted as a single vessel unless there was a break in
the continuity of the structure. The stained sections were
screened at 5 x magnification to identify the areas of highest
vascular density within the tumour from all tissue blocks.
These high-vascularity areas could occur anywhere within the
tumour, but occurred most frequently at the margins of the
carcinoma. Sclerotic areas, where microvessels were sparse,
and areas immediately adjacent to benign tissue were not
considered in vessel counts. Vessels were counted in the five
areas of highest vascular density at 200 x magnification
(x 20 objective and x 10 ocular, 0.785 mm2 per field). Mic-
rovessel count (MVC) was expressed as the mean number of
vessels in these areas. The two investigators' counts were
significantly correlated (by Spearman rank correlation test;
r = 0.621, P<0.01), therefore the average of the two inves-
tigators' counts was taken for further analysis.
Scoring ofPCNA
Only nuclear staining was accepted as positive (Figure 2). All
labelled nuclei were regarded as positive. Nuclei from more
than 500 tumour cells were counted microscopically among
the five areas with the highest density of PCNA expression
from all tissue blocks. The PCNA labelling index (PCNA LI)
was calculated as the percentage of positive cell nuclei.
Although the two investigators did not agree exactly regard-
ing the labelling index, a significant association was observed
between these two values (by Spearman rank correlation test;
r = 0.609, P<0.01). So the average of these two values was
used for the study.
Statistical methods
The relationship between MVC, PCNA LI and clinicopatho-
logical factors was examined by the Wilcoxon rank sum test.
Survival curves were calculated using the Kaplan-Meier
method and analysed by the log-rank test. The influence of
each variable on survival was assessed by Cox's proportional
hazard model (Cox, 1972). The relationship between MVC,
PCNA LI, various clinicopathological factors and the mode
of recurrence was examined by chi-square test or logistic
regression analysis. Statistical significance was defined as
P<0.05.
Results
MVC and PCNA LI
Microvessel count ranged from 5.1 to 50.0 with a mean
value, plus or minus the standard deviation, of 15.9 ± 10.3.
PCNA LI ranged from 7.7% to 76.5% with a mean value of
Figure 1 Immunohistochemical staining for F-VIII RA in cancer
tissues of the stomach. Expression of factor VIII-related antigen.
Microvessels represented by brown staining ofendothelium stand
out sharply from stromal tissue in a differentiated gastric
adenocarcinoma (original magnification x 200).
Figure 2 Immunohistochemical staining for PCNA in cancer
tissues of the stomach. Expression of proliferating cell nuclear
antigen. Nuclear staining in a high percentage of tumour cells in
a differentiated gastric adenocarcinoma (original magnification
x 400).
41.8% ± 19.5%. There was a wide standard deviation in both
MVC and PCNA LI. No significant association was observed
between these two variables (by Spearman rank correlation
test; r = 0.196, P = 0.069).
Relationship between MVC, PCNA LIand clinicopathological
factors
Neither MVC nor PCNA LI was associated with patients'
age and sex. Table I shows the correlation between MVC and
various clinicopathological factors. There was no statistically
significant association between MVC and histological type,
growth pattern or depth of invasion. However, the mic-
rovessel count in patients with lymph node metastases was
significantly higher (P<0.01) than in those without lymph
node metastases.
Table II shows the correlation between PCNA LI and
various clinicopathological factors. Significant differences
existed with respect to serosal invasion and lymph node
metastasis.
Association ofMVC, PCNA LIandotherfactors with survival
Among the 108 patients who underwent curative resection,
29 died of disease recurrence. To evaluate the associationAngiogenesis and prliferaton in gasticcarinoma
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Table I Correlation between clinicopathological factors and microvessel counts
Microvessel counts
Variable Mean ± s.d. (median, range) P-value
Serosal invasion
Negative (n = 66) 16.3 ± 11.3 (12.0, 3.0-35.5)
Positive (n = 42) 15.5 9.5 (13.5, 5.1-50.0) NS
Histological type
Differentiated (n = 50) 15.2 ± 10.4 (13.4, 3.0-50.0) NS
Undifferentiated (n = 58) 16.9 10.8 (14.0, 4.3-45.0)
Growth pattern
Expanding (n = 47) 16.3 + 11.8 (12.4, 4.5-44.3) NS
Infiltrative (n = 61) 16.0 ± 9.8 (14.4, 3.0-50.0)
Lymph node metastasis
Negative (n = 59) 13.3 ± 9.1 (10.2, 4.3-44.3)
Positive (n=49) 18.7± 11.3 (17.6, 3.0-50.0) <0.01
Table II Correlation between clinicopathological factors and PCNA labelling
index
PCNA labelling index
Variable Mean ± s.d. (median, range) P-value
Serosal invasion
Negative (n= 66) 35.5 13.2 (35.0,7.7-60.5) <005
Positive (n = 42) 48.5 16.9 (48.5, 10.0-76.5)
Histological type
Differentiated (n = 50) 38.4 16.4 (38.9, 7.7-74.2) NS
Undifferentiated (n = 58) 42.9 16.2 (10.0, 4.3-76.5)
Growth pattern
Expanding (n = 47) 33.7 ± 16.1 (29.5, 7.7-76.0) NS
Infiltrative (n = 61) 45.8 ± 14.5 (46.0, 15.1-76.5)
Lymph node metastasis
Negative (n = 59) 31.5 ± 12.6 (29.1, 7.7-67.0)
Positive (n = 49) 49.8 14.0 (48.5, 10.0-76.5) <0.01
between MVC, PCNA LI and overall survival, tumours were
separated on the basis of the mean values for MVC and
PCNA LI (MVC, 16; PCNA LI, 42). There was a significant
survival advantage in patients with low-MVC (less than 16)
tumours compared with those with high-MVC (16 or greater)
tumours (Figure 3a). The 5 year survival rate was 84.6%
(55/65) in the patients with low-MVC tumours, but only
55.8% (24/43) in the patients with high-MVC tumours. The 5
year survival rate in the patients with low-PCNA (less than
42) tumours was 86.9% (53/61), which was significantly
higher than in the patients with high-PCNA (42 or greater)
tumours, 55.8% (26/47) (Figure 3b).
The effects of variables presumably associated with prog-
nosis were studied by Cox's proportional hazard model. As a
result, only MVC and PCNA LI emerged as independent
prognostic factors (Table III). Of these parameters, PCNA
LI was the most important factor for predicting overall
survival, followed by MVC.
The relationship between the mode ofrecurrence, MVC and
PCNA LI
With regard to the site of the first relapse, 11 patients had
hepatic recurrences, 13 had peritoneal recurrences and five
had other sites of recurrence. The relationship between MVC,
PCNA LI and recurrence is shown in Table IV. Of the
patients with high-MVC tumours, 11 (57.9%) had hepatic
recurrence and seven (36.8%) had peritoneal recurrence. In
contrast, in patients with low-MVC tumours, six (60%) had
peritoneal recurrence and none had hepatic recurrence. The
frequency of hepatic recurrence was significantly (P<0.01)
higher in patients wtih high-MVC tumours than in those
with low-MVC tumours. In contrast, there was no significant
correlation between PCNA LI and the site of recurrence.
The rates of recurrence subdivided according to MVC and
PCNA LI are shown in Figure 4. The rate of recurrence was
only 2.4% (1/42) in patients with low-MVC and low-PCNA
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Figure 3 Survival curves of patients with gastric carcinoma sub-
divided according to MVC (a) or PCNA LI (b).
LI tumours, wich was significantly (P<0.01) lower than in
other patients. The highest rate of recurrence was observed in
patients with high-MVC and high-PCNA LI tumours. In this
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group, hepatic recurrences were observed in six (25.0%)
patients and peritoneal metastases were observed in five
(20.8%) patients.
We determined which factors were related to the site of
Table III Risk factors affecting overall survival determined by Cox's
proportional hazard model
95% confidence
Variable Hazard ratio interval P-value
Serosal invasion
Negative 1.04 0.80-2.71 0.076
Positive
Histological type
Differentiated 0.85 0.43-1.66 0.630
Undifferentiated
Growth pattern
Expanding 0.96 0.75-1.77 0.125
Infiltrative
Lymph node metastasis
Negative 1.34 0.66-3.41 0.061
Positive
Microvessel count
16 2.15 1.07-4.26 0.030 <16
PCNA labelling index
> 42 3.07 1.84-6.17 0.021
<42
Table IV Recurrent cases after curative resection
Rate ofrecurrence Location ofrecurrence
MVC Liver 57.9 (11/19)
> 16 44.2 Peritoneum 36.8 (7/19)
(n =43) (19/43) ]* Other 5.3 (1/19)
<16 15.4 j Liver 0(0/10) i
(n = 65) (10/65) Peritoneum 60.0 (6/10)
Other 40.0 (4/10)
PCN
42 4.7I Liver 28.6 (6/21) 42 47)
7 Peritoneum 47.6 (10/21) (n =4) (21.47) I* Other 23.8 (5/21) <42 13.1 J Liver 62.5 (5/8)
(n = 61) (8/61) Peritoneum 37.5 (3/8)
Other 0 (0/8)
*Statistical differences were calculated as P<0.01 by the chi-square
test.
recurrence by logistic regression analysis. Only MVC was
associated significantly with hepatic metastasis. However,
PCNA LI was not associated with any type of the recurrence
(Table V).
Discussion
It is now well established that vascularity and proliferative
activity play key roles in tumour growth, invasiveness and
metastasis (Van Dierendonck et al., 1989; Folkman, 1992;
Weidner et al., 1993). Recently, it has been suggested that the
degree of tumour angiogenesis is related to clinical outcome,
suggesting that angiogenic properties correlate with tumour
aggressiveness (Weidner et al., 1992; Gasparini et al., 1994).
In our study, there were no significant associations between
histological type, depth of invasion and MVC. However,
MVC was significantly higher in patients with lymph node
metastases than in those without such metastases. Weider et
al.. (1992) and Bosari et al. (1992) have also reported a
significant correlation between microvessel density and the
presence of metastatic disease in invasive breast cancer.
In addition, as measurement of cellular proliferative
activity has been suggested to be effective in judging the
malignant potential of various carcinomas (Van Dierendonck
et al., 1989), cell proliferation has been measured by means
of DNA ploidy analysis (Sowa et al., 1988), bromodeox-
yuridine (Wilson et al., 1986) or Ki-67 (Bouzubar et al.,
1989) immunostaining. PCNA is an auxiliary protein of
DNA polymerase 6 which plays a major role in DNA syn-
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Figure 4 Correlation between the rate of recurrence, MVC and
PCNA LI. =ii, liver; _, peritoneum, E1, other.
Table V Risk factors affecting recurrence by logistic regression analysis
Location ofrecurrence
Liver Peritoneum Other
Variable Relative risk P-value Relative risk P-value Relative risk P-value
Serosal invasion
Negative 1.49 0.138 1.93 0.044 0.06 0.953
Positive
Histological type
Differentiated 1.70 0.094 0.16 0.867 0.28 0.779
Undifferentiated
Growth pattern
Expanding 0.47 0.634 1.30 0.196 0.63 0.530
Infiltrative
Lymph node metastasis
Negative 0.86 0.391 0.21 0.833 1.17 0.244
Positive
Microvessel count
< 16 2.40 0.018 1.45 0.152 1.40 0.163
PCNA labelling index
)42 1.06 0.290 1.69 0.095 1.38 1.168 <42
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thesis and is thought to be expressed in the nuclei particular-
ly in late G1 and S-phases (Garcia et al., 1989; Landberg et
al., 1990). In this study, we used PCNA LI as a marker for
cell proliferation. As a result, we found that the higher grade
of PCNA expression was observed in patients with lymph
node metastasis or serosal invasion. Yonemura et al. (1993)
reported higher PCNA expression in patients with tumours
of diameter 6 cm or more and with lymph node metastasis.
With regard to prognosis, our study demonstrated
significantly poorer prognosis in patients with high-MVC
tumours or high-PCNA LI tumours, and both MVC and
PCNA LI were independent significant prognostic factors.
Weidner et al. (1992) have shown that both relapse-free and
overall survival rates decrease with increasing MVC. Toi et
al. (1993) have also reported that MVC is an independent
prognostic factor in patients with breast cancer. Similarly,
Yonemura et al. (1993) have reported that, among 120
patients with gastric cancer, those with a high PCNA LI
(40% or greater) had a significantly poorer prognosis than
those with a low PCNA LI (less than 40%). Furthermore,
with regard to sites of recurrence, an increased MVC was
significantly associated with hepatic recurrence. These results
suggest that both MVC and PCNA LI are prognostic
indicators and that MVC is an effective predictor of hepatic
recurrences in patients with gastric carcinoma.
Tumour cells are rarely shed into the circulation before the
primary tumour is vascularised (Folkman, 1990). It has been
shown that greater numbers of tumour vessels increase the
opportunity for tumour cells to enter the circulation (Liotta
et al., 1976). Moreover, newly formed capillaries have
fragmented basement membranes and are leaky compared
with mature vessels, making them penetrable by tumour cells
(Nagyl et al., 1988). Therefore, in the high-MVC tumours,
the metastatic process may be enhanced by the leaky nature
of newly formed blood vessels, which facilitates vascular
invasion. Our results confirm the association between high
vessel count in gastric carcinoma and the risk of hepatic
recurrence.
Various adjuvant therapies have been given to patients
with advanced gastric cancer to prevent recurrence after
resection. However, 50% of patients with advanced gastric
cancer survive after curative resection without post-operative
therapy (Miwa, 1984). Therefore, patients who need adjuvant
therapies should be selected by some indicators reflecting the
probability of recurrence. Thus, MVC and PCNA LI in
resected specimens may be suitable methods of identifying
patients who need additional therapy post-operatively.
Recently, TNP-470, an analogue of fumagillin derived
from Aspergillus fumigatus, has been shown to inhibit
angiogenesis and the growth of some tumours (Ingber et al.,
1990; Yamaoka et al., 1993). Such agents may prove to be
valuable anti-tumour chemotherapeutic agents, especially in
patients with high-MVC tumours.
In summary, this retrospective study demonstrates that
both MVC and PCNA.LI may be good prognostic indicators
and that MVC may be useful in predicting the hepatic recur-
rence in patients with gastric carcinoma. If these findings are
confirmed in larger studies, it will be possible to add MVC
and PCNA LI to other prognostic factors to identify patients
at high risk of recurrence and to guide decisions on addi-
tional therapy after surgery.
Abbrevations: F-VIII RA, factor VIII-related antigen; PCNA, pro-
liferating cell nuclear antigen.
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